We are live on ! Find out more
HUMA icon

Humacyte
HUMA

28 hedge funds and large institutions have $30.9M invested in Humacyte in 2021 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

56% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 9

22% more funds holding

Funds holding: 23 → 28 (+5)

18% more capital invested

Capital invested by funds: $26.2M → $30.9M (+$4.72M)

5.94% more ownership

Funds ownership: 23.31% → 29.25% (+5.9%)

50% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 6

Holders
28
Holders Change
+5
Holders Change %
+21.74%
% of All Funds
0.49%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
3
Reduced
6
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
ACM
Altium Capital Management
New York
+$2.83M
2
CAC
Cowen and Company
New York
+$2.48M
3
PSAMP
P. Schoenfeld Asset Management (PSAM)
New York
+$2.06M
4
ACA
Arena Capital Advisors
California
+$1.03M
5
TCM
Tenor Capital Management
New York
+$1.03M

Top Sellers

1
AGM
Alpine Global Management
New York
-$3.21M
2
Tudor Investment Corp
Tudor Investment Corp
Connecticut
-$1.45M
3
Marshall Wace
Marshall Wace
United Kingdom
-$494K
4
NM
Newtyn Management
New York
-$437K
5
EP
Eversept Partners
New York
-$350K
Name Holding Trade Value Shares
Change 		Change in
Stake
MS
1
Maven Securities
Jersey
$5.09M -$117K -11,400 -2%
Tudor Investment Corp
2
Tudor Investment Corp
Connecticut
$4.1M -$1.45M -140,303 -26%
UOC
3
UBS O'Connor
Illinois
$3.06M -$39.1K -3,800 -1%
ACM
4
Altium Capital Management
New York
$2.8M +$2.83M +275,000 New
CAC
5
Cowen and Company
New York
$2.45M +$2.48M +240,690 New
AGM
6
Alpine Global Management
New York
$2.14M -$3.21M -311,412 -60%
EP
7
Eversept Partners
New York
$2.09M -$350K -34,000 -14%
PSAMP
8
P. Schoenfeld Asset Management (PSAM)
New York
$2.04M +$2.06M +200,000 New
OPU
9
Omni Partners US
California
$1.96M +$1.98M +191,925 New
ACA
10
Arena Capital Advisors
California
$1.02M +$1.03M +100,000 New
TCM
11
Tenor Capital Management
New York
$1.02M +$1.03M +100,000 New
WAM
12
Wolverine Asset Management
Illinois
$565K +$518K +50,289 +964%
Millennium Management
13
Millennium Management
New York
$557K +$84.4K +8,194 +18%
WRBC
14
W.R. Berkley Corp
Connecticut
$426K – – –
Verition Fund Management
15
Verition Fund Management
Connecticut
$306K – – –
EP
16
Eudaimonia Partners
Tennessee
$272K +$275K +26,694 New
HI
17
HBK Investments
Texas
$255K +$258K +25,000 New
EAM
18
Exos Asset Management
New York
$158K +$160K +15,549 New
PTC
19
Philadelphia Trust Company
Pennsylvania
$153K – – –
FM
20
Family Management
New York
$146K +$148K +14,324 New
Osaic Holdings
21
Osaic Holdings
Arizona
$128K +$119K +11,550 +1,155%
VFIC
22
Valley Forge Investment Consultants
Pennsylvania
$102K +$103K +10,000 New
Wells Fargo
23
Wells Fargo
California
$15K – – –
AWM
24
Avior Wealth Management
Nebraska
$10K – – –
UBS Group
25
UBS Group
Switzerland
$6K +$5.57K +541 New
1
2

HUMA Hedge Fund Activity: Q2 2021 in Review

28 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Humacyte (HUMA) for Q2 2021, worth a combined $30.9M — up 18% from $26.2M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new HUMA positions and 9 closed out — a net gain of 5 holders — while 3 added to existing stakes and 6 trimmed.

The largest buyer was Altium Capital Management, opening a new position worth an estimated $2.83M. The largest seller was Alpine Global Management, cutting an estimated $3.21M.

  • 28 institutional investors held Humacyte (HUMA) as of Q2 2021, up from 23 in Q1 2021.
  • Funds reported $30.9M of Humacyte stock for Q2 2021, up 18% quarter-over-quarter.
  • 14 funds opened new Humacyte positions in Q2 2021 and 9 closed out, a net change of +5 holders.
  • The largest Humacyte buyer in Q2 2021 was Altium Capital Management, an estimated $2.83M added.
  • The largest Humacyte seller in Q2 2021 was Alpine Global Management, an estimated $3.21M sold.

Based on aggregated 13F filings for Q2 2021.